1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Takeda Pharmaceutical Company Limited
  6. Summary
    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  05/18 02:00:00 am EDT
3690.00 JPY   +0.30%
05/12Japan Index Ends in Red; Toyota Clocks Record-High FY22 Attributable Income but Projects Decline Next Fiscal
MT
05/11Takeda Pharmaceutical's FY22 Attributable Profit Falls 39%
MT
05/11GLOBAL MARKETS LIVE : Coinbase, Roblox, Apple, EA, Hasbro...
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Japan Exchange
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
3616(c) 3671(c) 3661(c) 3679(c) 3690(c) Last
7 106 700 5 973 700 3 785 700 3 689 500 5 595 100 Volume
-3.19% +1.52% -0.27% +0.49% +0.30% Change
More quotes
Estimated financial data (e)
Sales 2022 3 490 B 26 982 M 26 982 M
Net income 2022 239 B 1 847 M 1 847 M
Net Debt 2022 3 299 B 25 501 M 25 501 M
P/E ratio 2022 24,0x
Yield 2022 4,89%
Sales 2023 3 561 B 27 533 M 27 533 M
Net income 2023 311 B 2 403 M 2 403 M
Net Debt 2023 2 767 B 21 390 M 21 390 M
P/E ratio 2023 18,5x
Yield 2023 4,89%
Capitalization 5 679 B 43 902 M 43 902 M
EV / Sales 2022 2,57x
EV / Sales 2023 2,37x
Nbr of Employees 47 099
Free-Float 97,2%
More Financials
Company
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United... 
Sector
Pharmaceuticals
Calendar
06/29Shareholder meeting
More about the company
Ratings of Takeda Pharmaceutical Company Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
05/12Japan Index Ends in Red; Toyota Clocks Record-High FY22 Attributable Income but Project..
MT
05/11Takeda Pharmaceutical's FY22 Attributable Profit Falls 39%
MT
05/11GLOBAL MARKETS LIVE : Coinbase, Roblox, Apple, EA, Hasbro...
05/11TRANSCRIPT : Takeda Pharmaceutical Company Limited, Q4 2022 Earnings Call, May 11, 2022
CI
05/11TRANSCRIPT : Takeda Pharmaceutical Company Limited, 2022 Earnings Call, May 11, 2022
CI
05/11Takeda Pharmaceutical Posts Higher Profit, Revenue in Fiscal 2021
MT
05/11Takeda Pharmaceutical Posted Fourth-Quarter Net Loss
DJ
05/11Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
BU
05/11Takeda Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the F..
CI
05/11Takeda Pharmaceutical Company Limited Declares Dividend for the Year Ended March 31, 20..
CI
05/11Takeda Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended ..
CI
04/29OncoSec Medical Names Robert Arch CEO; Shares Rise Early
MT
04/29HilleVax Shares Gain Ground in Trading Debut After Upsized IPO
DJ
04/28CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient ..
AQ
04/27Takeda Recognized as 2022 ISPE Facility of the Year Awards Winner in Two Categories
AQ
More news
News in other languages on TAKEDA PHARMACEUTICAL COMPANY LIMITED
05/14Takeda annonce de solides résultats pour l'exercice 2021á; prévision de maintien de la ..
05/13Takeda ofrece sólidos resultados para el año fiscal 2021; se espera que el crecimiento ..
05/13Takeda liefert starke Ergebnisse für das GJ2021; anhaltende Wachstumsdynamik für das GJ..
05/12L'indice japonais termine dans le rouge ; Toyota enregistre un revenu attribuable recor..
05/11Le bénéfice attribuable de Takeda Pharmaceutical pour l'exercice 22 chute de 39 %.
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 3 679,00 JPY
Average target price 4 302,67 JPY
Spread / Average Target 17,0%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED17.28%43 902
JOHNSON & JOHNSON4.53%470 547
PFIZER, INC.-13.06%288 063
ABBVIE INC.14.31%273 513
ELI LILLY AND COMPANY9.12%271 308
ROCHE HOLDING AG-14.97%263 868